• Journal of Pharmaceutical Investigation
• /
• 제40권spc호
• /
• pp.83-95
• /
• 2010

Over the years, nanoparticle drug delivery systems have demonstrated versatile potentials in biological, medical and pharmaceutical applications. In the pharmaceutical industry nanotechnology research has mainly focused on providing controlled drug release, targeting their delivery to specific organs, and developing parenteral formulations for poorly water soluble drugs to improve their bioavailability. Achievement in polymer industry has generated numerous polymers applicable to designing nanoparticles. From viewpoints of product development, a nanocarrier material should meet requirements for biodegradability, biocompatibility, availability, and regulatory approval crieteria. Albumin is indeed a material that fulfills such requirements. Also, the commercialization of a first albumin-bound paclitaxel nanoparticle product (Abraxane$^{TM}$) has sparked renewed interests in the application of albumin in the development of nanoparticle formulations. This paper reviews the intrinsic properties of albumin, its suitability as a nanocarrier material, and albumin-based parenteral formulation approaches. Particularly discussed in detail are albumin-based particulate injectables such as Abraxane$^{TM}$. Information on key roles of albumin in the nab$^{TM}$ technology and representative manufacturing processes of albumin particulate products are provided. It is likely that albumin-based particulate technology would extend its applications in delivering drugs, polypeptides, proteins, vaccines, nucleic acids, and genes.

• Journal of Yeungnam Medical Science
• /
• 제28권2호
• /
• pp.145-152
• /
• 2011

Background: To evaluate the changes in the radiation dose and temperature distribution on irradiated egg albumin and nanoparticle ($Fe_3O_4$) powder mixed egg albumin. Methods: A new type of phantom was designed by fabricating a $30{\times}30{\times}30cm$ acryl square inside a $3{\times}3{\times}3cm$ small square and dividing it into two parts. In the control group, only egg albumin was irradiated, and in the test group, 25 nm 20 mg/cc, 25 nm 40 mg/cc, and 1 um 40mg/cc nanoparticles with egg albumin were irradiated. The radiation isodose distributions and temperature changes were then observed. Results: No significant changes were observed in the radiation dose and temperature distribution. Conclusion: The nanoparticles were considered not to have had any effect on the radiation dose and temperature distribution under the experimental conditions. Further studies can be conducted based on the changes in the mixture material.

• Journal of Digestive Cancer Research
• /
• 제5권1호
• /
• pp.62-65
• /
• 2017

2013년 실제 임상에 Gemcitabine과 nab-paclitaxel 병용요법이 적용된 후 NCCN Guideline에서 절제 불가능한 췌장암 환자에서 일차적으로 선택할 수 있는 약제로 제시하고 있다. 이 병용요법으로 인한 가장 흔한 Grade 3 부작용으로는 호중구감소증, 피로, 말초신경병증이 보고되었으며, 심장독성은 흔하지 않다. 본 증례에서는 심장표지자의 상승 및 심초음파에서의 우측관상동맥의 허혈 손상이 확인되어 병용요법으로 인한 심장 허혈 손상 및 심낭삼출물이 발생하여, 심장성 쇼크로 사망하였을 것으로 추정해 볼 수 있다. Gemcitabine과 nab-paclitaxel에 의한 심장 허혈 손상의 더 많은 증례 보고 및 연구가 필요하며, 병용요법을 투여 받는 환자들에 대한 심장독성에 대하여 주의 깊은 관찰이 필요할 것으로 생각된다.

• 청정기술
• /
• 제27권1호
• /
• pp.55-60
• /
• 2021

항생제는 감염병 환자의 치료, 농수축산업의 생산성 향상을 위한 목적으로 광범위하게 사용되는 약물이다. 그러나 항생제 과용 및 낮은 생분해성으로 인해 상당량이 하수로 누출되어 환경오염을 유발하며 내성 박테리아 출현을 촉진하고 있다. 본 연구에서는 생분해성 혈청 단백질인 알부민을 항생제 흡착제로 사용하기 위한 가능성을 탐구하였다. 혈청 알부민은 다양한 대사 산물과 호르몬을 모든 조직의 혈관 외 공간으로 운반하는 천연 혈액 단백질이다. 혈청 알부민은 수용성이 높지만 이온성, 친수성 또는 소수성 분자를 쉽게 수용하는 고유 결합 부위를 가지고 있어 나노 흡착제로 유망한 물질이다. 코아세르베이션(coacervation)을 유도하기 위해 탈용매제인 에탄올을 알부민 수용액에 적가하여 150 ~ 170 nm 크기 범위의 알부민 나노 입자로 탈수화 및 액-액분리 하였다. 글루타르알데히드 가교제를 첨가할 경우 알부민 나노입자의 크기 안정성 및 동질성이 증가하였다. 항생제 아목시실린에 대한 알부민 나노입자의 흡착능 평가에서 가교제 사용 농도, pH에 따른 흡착능의 차이가 관찰되었다. 분광광도법으로 측정한 알부민 나노입자의 단위질량당(mg) 최대 흡착능은 pH 4.0 수용액에서 아목시실린 12.4 마이크로그램(㎍)이다. 이러한 결과는 물에서 항생제를 제거하는 천연 나노 흡착제를 제조하기 위한 구성 물질로서 혈청 알부민의 잠재력을 보여준다.

• Bulletin of the Korean Chemical Society
• /
• 제35권9호
• /
• pp.2621-2624
• /
• 2014

The rapid and spontaneous adsorption of proteins on nanoparticle (NP) surfaces in biological fluids such as blood is an important phenomenon as it possibly determines "what the cells see" and, thus, the fates of NPs in living organisms. In order to quantitatively understand protein coronas at the molecular level, we investigated human serum albumin (HSA) coronas that were produced on silica NPs of 20 nm and 50 nm diameters using conventional gel electrophoresis. Analysis of the concentration dependence of protein adsorption showed that HSA coronas preferentially formed a monolayer on silica NPs and revealed the presence of hard protein coronas. HSA adsorption was clearly dependent on NP size, and this might be due to the different surface curvatures of NPs of different sizes.

• Journal of Digestive Cancer Research
• /
• 제7권1호
• /
• pp.22-25
• /
• 2019

췌장암은 예후가 불량한 암으로 진단 당시 진행된 상태로 수술적 치료의 적응증이 되지 못해 고식적 항암 치료를 받는 경우가 대부분이다. 진단 당시 전이성 병변을 동반한 췌장암인 경우 예후가 좋지 않을 것으로 예상하지만 고식적 목적으로 항암치료를 한 결과 매우 좋은 반응을 보였던 증례를 문헌 고찰과 함께 보고한다.

• Bulletin of the Korean Chemical Society
• /
• 제32권10호
• /
• pp.3581-3586
• /
• 2011

Silver nanoparticle (Ag-NPs)-immobilized and amine-functionalized carbon nanotubes (MWCNTs), MWCNT-Ag-$NH_2$, were easily prepared in order to develop an efficient delivery system of biomolecules without complicated processes of manufacture. For this, Ag-NPs-immobilized MWCNTs, MWCNT-Ag, were initially prepared in order to create large surface area to enable more efficient linkage with guest-molecules using pristine MWCNTs. The Ag-NPs on MWCNTs were further positively functionalized with 2-aminoethanthiol to allow ionic linkage with biomolecules. Ultimately, the positively charged delivery system proved to be highly effective for the binding capacity of bovine serum albumin (BSA) as a negatively charged model protein, when compared to that of lysozyme used as a positively charged model protein. The releasing profile of BSA was observed in almost linear pattern for about two weeks in a saline solution. This study demonstrated the potential usefulness of the pristine MWCNTs in conjunction with Ag-NPs for the selective delivery of many (negatively or positively) charged biomolecules including proteins and genes.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권17호
• /
• pp.7453-7457
• /
• 2014

Objective: To observe the efficacy and toxicity of nanoparticle albumin bound paclitaxel (nab-paclitaxel) plus platinum agent (cisplatin or carboplatin) as first line treatment for stage III/IV squamous non-small-cell lung cancer (NSCLC). Methods: Forty chemotherapy naive patients with stage III/IV squamous NSCLC received nab-paclitaxel $125mg/m^2$ on day 1 and day 8, cisplatin $75mg/m^2$ on day 1, carboplatin area under the concentration-time curve of 5 (AUC=5) on day 1. One cycle of treatment was 3 weeks, and at least two were completed in each case. Results: Of the 40 patients who participated in the study, 25 achieved partial responses (PR), 12 reached a stage of stable disease (SD), and 3 suffered progressive disease (PD). The overall response rate (ORR) was 62.5% and the disease control rate (DCR) was 92.5%. Of the 20 patients without surgery or radiotherapy, 10 achieved PR, 7 reached a stage of SD, and 3 PD. The ORR was 50.0% and the DCR was 85.0%. The median progression-free survival time (PFS) of patients without surgery or radiotherapy was 5.0 months. Of the 20 patients receiving surgery or radiotherapy, 15 had PR and 5 p had SD, with an ORR of 75.0% and a DCR of 85.0%. Specifically, the DDP arm demonstrated a significantly higher ORR than the CBP arm (100%vs 54.5%, P<0.05). Common treatment related adverse events were myelosuppression, gastrointestinal response, baldness and neurotoxicity, most of which were grade 1 to 2. Conclusion: Nab-paclitaxel plus platinum agent (cisplatin or carboplatin) is effective as a first-line chemotheraphy for stage III/IV squamous NSCLC, and its adverse effects are tolerable.

• Bulletin of the Korean Chemical Society
• /
• 제30권12호
• /
• pp.2905-2908
• /
• 2009

Immuno-sensing for high accurate and selective sensing was performed by fluorescence spectroscopy and surface plasmon resonance (SPR), respectively. Engineered assembly of two fluorescent quantum dots (QDs) with bovine serum albumin (BSA) and anti-BSA was fabricated in PBS buffer for fluorescence analysis of fluorescence resonance energy transfer (FRET). Furthermore, the same bio-moieties were immobilized on Au plates for SPR analysis. Naturally-driven binding affinity of immuno-moieties induced FRET and plasmon resonance angle shift in the nanoscale sensing system. Interestingly, the sensing ranges were uniquely different in two systems: e.g., SPR spectroscopy was suitable for highly accurate analysis to measure in the range of 10$^{-15{\sim}-10$ng/mL while the QD fluorescent sensing system was relatively lower sensing ranges in 10$^{-10{\sim}-6$ng/mL. However, the QD sensing system was larger than the SPR sensing system in terms of sensing capacity per one specimen. It is, therefore, suggested that a mutual assistance of FRET and SPR combined sensing system would be a potentially promising candidate for high accuracy and reliable in situ sensing system of immune-related diseases.

• Journal of Digestive Cancer Research
• /
• 제6권2호
• /
• pp.64-68
• /
• 2018

Pancreatic ductal adenocarcinoma is a dismal prognosis and 5^th leading cause of cancer related death in Korea. A large proportion of patients are diagnosed at advanced or metastatic stage. Therefore systemic chemotherapy has become the mainstay of treatment for pancreatic cancer. For most patients advanced or metastatic pancreatic cancer that has a good Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1, we can recommend for FOLFIRINOX (leucovorin, 5-fluorouracil [5-FU], irinotecan and oxaliplatin) and gemcitabine plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel). Currently, steps towards improved therapeutic efficacy of palliative chemotherapy have been made by introducing these regimens. For patients with an ECOG PS of 2, gemcitabine monotherapy or S1 alone is recommended. The second-line therapy for patients initially treated with gemcitabine-based chemotherapy includes provide FOLFOX (leucovorin, 5-FU, and oxaliplatin), capecitabine plus oxaliplatin, and 5-FU plus liposomal irinotecan. The gemcitabine-based chemotherapy is a reasonable choice for patients treated with FOLFIRINOX. Currently, studies on selecting patients for biomarkers related to molecular biologic features of tumors are underway for the realization of precise medicine, and the development and verification of preclinical models for the development of new therapeutic agents are being carried out continuously.